Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-TIL Plus Tislelizumab as Adjuvant Therapy in NSCLC
NCT07330037Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of L-TIL cells in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: 2-year Disease Free Survival. Started Dec 2025; status: recruiting.
02
Drugs
L-TIL cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07330037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330037.